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Abstract
Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target
of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function. Preliminary
observational data suggest the potential for ovarian toxicity but this issue has not been studied in randomized controlled
trials. We reviewed the self-reported occurrence of menstrual cycle disturbances and the appearance of ovarian cysts post
hoc in an open label randomized controlled phase II trial conducted at the University Hospital Zu¨rich between March 2006
and March 2010. Adult females with autosomal dominant polycystic kidney disease, an inherited kidney disease not known
to affect ovarian morphology and function, were treated with 1.3 to 1.5 mg sirolimus per day for a median of 19 months
(N = 21) or standard care (N = 18). Sirolimus increased the risk of both oligoamenorrhea (hazard ratio [HR] 4.3, 95%
confidence interval [CI] 1.1 to 29) and ovarian cysts (HR 4.4, CI 1.1 to 26); one patient was cystectomized five months after
starting treatment with sirolimus. We also studied mechanisms of sirolimus-associated ovarian toxicity in rats. Sirolimus
amplified signaling in rat ovarian follicles through the pro-proliferative phosphatidylinositol 3-kinase pathway. Low dose
oral sirolimus increases the risk of menstrual cycle disturbances and ovarian cysts and monitoring of sirolimus-associated
ovarian toxicity is warranted and might guide clinical practice with mammalian target of rapamycin inhibitors.
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Introduction
Sirolimus (Rapamune, Pfizer, New York, NY, USA) is a potent
immunosuppressive and anti-proliferative drug which blocks the
mammalian target of rapamycin (mTOR). MTOR is a key
regulatory kinase which is also known to regulate ovarian function
[1]. The drug has been approved by both the US Food and Drug
Administration and the European Medicines Agency for the
prevention of renal allograft rejection.
Most of our knowledge regarding sirolimus toxicity has been
derived from kidney transplant efficacy trials. However there were
no reports of menstrual cycle disturbances and ovarian cyst
formation in three large clinical trials [2,3,4], although these
adverse events were reported in three case series [5,6,7]. Ovarian
dysfunction is difficult to recognize in clinical trials: symptoms are
often non-specific and can be wrongly attributed to concomitant
medication or comorbidities [8].
Aside from organ transplantation, sirolimus is being assessed for
clinical effectiveness in several cancers and in other proliferative
disorders, including autosomal dominant polycystic kidney disease
(ADPKD). ADPKD is characterized by the growth of kidney cysts;
the disease itself is not known to affect ovarian morphology and
function [9,10,11]. Although sirolimus shows promise in rodent
polycystic kidney disease models [12,13,14,15,16,17], 18 months
treatment with sirolimus did not slow the growth of kidney cysts in
adults with ADPKD [18].
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Animal and observational data suggest the potential for ovarian
toxicity but this issue has not been considered in previous trials
[19]. We sought to determine whether sirolimus causes menstrual
cycle disturbances and ovarian cysts in adults with ADPKD
enrolled in a randomized controlled trial. Here we extend a letter
[20] warning of an increased risk of ovarian toxicity among
patients receiving sirolimus; we provide full details and suggest a
possible mechanism of toxicity.
Methods
Trial Setting
The SUISSE ADPKD study was a randomized controlled
phase II trial carried out to determine whether 18 months of
treatment with sirolimus slows kidney growth in adults with
ADPKD. The occurrence of menstrual cycle disturbances and
ovarian cysts were pre-defined secondary endpoints in the
statistical analysis plan [18]. From March 2006 through March
2008 we enrolled 100 patients (39 females) with ADPKD at the
University Hospital Zurich [21]. These patients were between 18
and 40 years of age, with an estimated creatinine clearance of at
least 70 milliliter per minute. The trial was run according to the
principles of the Declaration of Helsinki, the Good Clinical
Practice guidelines of the International Conference on Harmoni-
zation, and local regulatory requirements. The protocol for this
trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1. The
medical ethics committee of the Canton Zu¨rich, Switzerland
(SPUK) approved the trial protocol [22]. All patients gave written
informed consent.
After a run-in period of 6 months, patients were randomly
assigned to receive either 18 months treatment with sirolimus
(target dose 2 mg daily) or standard care. Standard care consisted
of blood pressure control (office systolic and diastolic blood
pressure targets below 130 and 85 mm Hg respectively), prompt
antibiotic treatment of kidney cyst infections, and avoidance of
potentially nephrotoxic substances. The sirolimus dose was
adjusted to achieve steady-state levels between 4 and 10 mg per
liter, determined by liquid chromatography–mass spectrometry
from whole blood. Patient adherence to sirolimus was assessed
using an electronic system (MEMSTM, Aardex Group, Ltd., Sion,
Switzerland).
Wyeth (now Pfizer) had no role in the trial design, collection,
analysis and interpretation of the data or the writing of the report.
Andreas L. Serra and James Young had full access to the study
data and take responsibility for the integrity of the data and the
accuracy of the data analysis.
Assessment of trial outcomes
At enrollment, randomization, 6, 12 and 18 months patients
were asked if they had any menstrual cycle abnormalities in the
past 6 months. Oligoamenorrhea was defined as no menstrual
period for 3 months or more when one should have occurred, or
an interval of more than 35 days between menstrual periods. Our
definition of oligoamenorrhea was based on criteria used in
epidemiologic studies [23,24].
Abdominal magnetic resonance imaging (MRI) without contrast
material was performed every 6 months using a 1.5T MR scanner
(Signa Echospeed Excite HD or HDx, General Electrics (GE)
Healthcare, Waukesha, Wisconsin, USA).[25] At each point in
time, the number and diameter of right and left ovarian cysts
greater than 2 cm in diameter were measured on coronal T2-
weighted single-shot fast spin echo sequences acquired in breath
hold technique using a dedicated computer workstation (Advan-
tage Windows Workstation 4.4, GE Healthcare). The workstation
observer was blinded to all clinical data and patients were
measured in random order.
Statistical Analysis
Analyses of prevalence and incidence were carried out using
logistic and Cox proportional hazards regression in SAS version
9.2 (Cary, NC, USA). Outcomes for logistic regression were any
patient report of oligoamenorrhea and any detected ovarian cyst
greater than 2 cm in diameter during the 18 months treatment
period. Outcomes for Cox proportional hazards regression were
time to a first report of oligoamenorrhea in those without
oligoamenorrhea at randomization, and time to a first ovarian
cyst greater than 2 cm in diameter in those without such cysts at
randomization. Since these outcomes can only be assessed at each
visit we used a discrete time version of the Cox proportional
hazards model.[26] For both logistic and proportional hazard
regression, we report profile likelihood and exact confidence
intervals. With few events, maximum likelihood estimates for odds
and hazard ratios tend to be biased away from a value of one
[27,28] however, exact confidence intervals tend to be wider than
is strictly necessary [29,30]. With few events, it is not sensible to
include covariates in any of our models and we estimate only the
effect of the randomized treatment on outcome. The discrete time
version of the Cox proportional hazards model has a comple-
mentary log-log link function and an offset to adjust for some slight
variation in the time between visits scheduled 6 months apart [26].
However the exact estimate must be based on a model with a logit
link function and no offset.
Animal Studies
The sirolimus-associated effects on the mTOR signaling
pathway in ovaries were examined by Western blotting and
immunohistochemistry in rats given oral sirolimus. The animal
study was approved by the animal health regulatory agency of the
Canton Zu¨rich, Switzerland.
Animal Study Procedures
Female 4 week old Wistar rats were given daily 3.0 milligram
per kilogram body weight sirolimus (N=4) or vehicle (N= 4) by
gavage feeding. The rats were sacrificed during pro-estrus three
weeks after initiation of treatment at six PM and serum levels of
follicle and luteal stimulating hormones were measured by enzyme
linked immunoassay according to the manufactures’ protocol.
Western Blots
Ovaries were homogenized with ice-cold lysis buffer containing
40 mM Hepes, 120 mM NaCl, 1 mM ethylenediaminetetraacetic
acid (EDTA), 10 mM potassium pyrophosphate, 10 mM glycerol
phosphate, 50 mM NaF, 0.5 mM NaVO3, 1% Triton, and
protease inhibitor (pH 7.6). Tissue lysates were cleared by
centrifugation. Equal amounts of lysates were resolved on sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to nitrocellulose membranes, and probed with
antibodies. Cell Signaling Technology supplied antibodies against
Akt Ser473, p70 S6K Thr421/Ser424 and p70 S6K; Abcam supplied
an anti-Akt antibody; Millipore supplied an anti- glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) antibody.
Immunohistochemistry
Paraffin-embedded sections were cut and stained by the
immunoperoxidase technique, following standard methods of
deparaffinization, antigen retrieval, primary antibody incubation
Toxicity of Sirolimus
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with either anti-Akt Ser473 (Cell Signaling) or anti-p70 S6K
Thr421 (GenWay), secondary antibody incubation, 3,3-diamino-
benzidine (DAB) incubation, and counterstaining with methyl
green.
Results
Patients
Of the 39 females enrolled, 21 were randomized to receive
sirolimus and 18 to receive standard care. Follow-up was complete
in all but one patient receiving sirolimus who withdrew at 6
months (Figure 1). At randomization, patient characteristics were
similar between the groups (Table 1): 2 patients in the sirolimus
group and 1 patient in the control group reported at least one
episode of oligoamenorrhea in the last 6 months (Table 2). At
randomization, ovarian cysts were recorded in 2 patients in the
sirolimus group and in 4 patients in the control group (Table 2).
Median (interquartile range [IQR]) follow up time after
randomization was 19 months (19–20) and 19 months (18–20) in
the sirolimus and control groups, respectively. Both the numbers
of missing reports of menstrual cycle disturbances and the number
of unreadable MRI scans were lower among patients in the
sirolimus group (Table 2).
Trial Outcomes
A total of 11 out of 21 patients in the sirolimus group reported
oligoamenorrhea at any visit after randomization, compared to 3
out of 18 patients in the control group (Table 2). Five patients in
the sirolimus group reported more than one episode of
oligoamenorrhea during the trial whereas only one patient in
the control group reported more than one episode of oligoame-
norrhea (Figure 2).
Ovarian cysts were observed in 12 out of 21 patients in the
sirolimus group, compared to 5 out of 18 patients in the control
group (Table 2). Six patients in the sirolimus group had ovarian
cysts at more than one visit after randomization compared to only
two patients in the control group (Figure 2). One patient
presented with acute abdominal pain and a large cyst of the left
ovary while receiving sirolimus and was cystectomized at 164 days
after randomization.
Differences in cycle disturbances were apparent in those not on
oral contraceptives – 8 out of 11 and 2 out of 9 patients in the
sirolimus and control groups; but were less apparent in those on
oral contraceptives – 3 out of 10 and 1 out of 9 patients in the
sirolimus and control groups. Differences in ovarian cysts between
sirolimus and control did not seem to depend on the contraceptive
Figure 1. Enrollment and Outcomes.
doi:10.1371/journal.pone.0045868.g001
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Table 1. Characteristics of patients at randomization.*
Characteristic – values are means (standard deviation) or numbers (percent) Sirolimus Control
(N=21) (N=18)
Age – year 31 (8) 32 (7)
BMI – kilogram per m2{ 22 (3) 22 (3)
Blood pressure – mm Hg
Systolic 132 (12) 120 (11)
Diastolic 83 (11) 78 (10)
Estimated GFR – ml/min per 1.73 m21 88 (20) 96 (16)
Chronic kidney disease stage – no. (%)"
1 10 (48) 11 (61)
2 10 (48) 7 (39)
3 1 (5) 0
Menarche – year{ 13 (2) 13 (2)
Parity – no. (%){
Nulliparous 13 (62) 14 (78)
1–2 7 (33) 4 (22)
.2 1 (5) 0
Contraception – no. (%){
Hormonal 10 (48) 9 (50)
Barrier method 11 (52) 9 (50)
*From New England Journal of Medicine, Ovarian toxicity from sirolimus, Braun M, Young J, Reiner CS, Poster D, Wu¨thrich RP, Serra AL. 366(11):1062-4. Copyright 
(2012) Massachusetts Medical Society. Reprinted with permission.
{The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
1The glomerular filtration rate (GFR) was estimated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [48].
"Chronic kidney disease was classified according to the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation. Stage 1 denotes a glomerular
filtration rate (GFR) of 90 ml or more per minute per 1.73 m2 of body-surface area; stage 2, a GFR of 60 to 89 ml per minute; and stage 3, a GFR of 30 to 59 ml per
minute.
{Patients’ self-reported medical histories at randomization.
doi:10.1371/journal.pone.0045868.t001
Table 2. Number of patients with oligoamenorrhea and ovarian cysts.*
Number of patients (percent) [missing if any] Sirolimus N=21 Control N=18
Oligoamenorrhea{
Enrollment 3 (14) 2 (12) [1]
Randomization 2 (10) [1] 1 (7) [3]
6 months 9 (43) 2 (11)
12 months 5 (25) [1] 2 (11)
18 months 5 (26) [2] 1 (6)
Any visit after randomization 11 (52) 3 (17)
Ovarian cysts{
Enrollment 4 (19) 4 (25) [2]
Randomization 2 (10) 4 (24) [1]
6 months 6 (29) 2 (14) [4]
12 months 6 (30) [1] 3 (18) [1]
18 months 7 (39) [3] 2 (12) [1]
Any visit after randomization 12 (57) 5 (28)
*From New England Journal of Medicine, Ovarian toxicity from sirolimus, Braun M, Young J, Reiner CS, Poster D, Wu¨thrich RP, Serra AL. 366(11):1062-4. Copyright 
(2012) Massachusetts Medical Society. Reprinted with permission.
{Patients’ self-reported events during the 6 months before the visit.
{Assessed by two independent observers – there was no disagreement between observers.
doi:10.1371/journal.pone.0045868.t002
Toxicity of Sirolimus
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e45868
Toxicity of Sirolimus
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e45868
method (barrier methods: 7 out of 11 and 3 out of 9 patients in the
sirolimus and control groups; oral contraceptives: 5 out of 10 and 2
out of 9 patients in the sirolimus and control groups).
Although imprecise, estimates of odds and hazard ratios suggest
that the prevalence and incidence of both oligoamenorrhea and
ovarian cysts were higher among patients receiving sirolimus
(Table 3).
Adherence to Sirolimus
Mean sirolimus doses were between 1.2 and 1.5 milligram per
day and the sirolimus steady-state blood levels between 3.5 and 4.7
microgram per liter (Table 4). Patient adherence to sirolimus,
measured by percentage of correct dosing, was 95% over the 18
month treatment period (Figure 3).
Animal Studies
Rats given sirolimus 3.0 milligram per kilogram per day for
three weeks, a dose that produces blood concentrations similar to
those in patients [31], had lower body weight: 260614 g (mean 6
standard deviation) in the sirolimus group and 291617 g in the
control group. The ratios of ovaries to body weight were similar
between groups: 0.04560.013 in the sirolimus group and
0.03960.001 in the control group. We did not find evidence for
an increased frequency of ovarian cysts: two observers blinded for
the treatment allocation reviewed the histological sections and
reported no difference in the number and morphology of ovarian
follicles. The automatically calculated ratios of blank space to total
ovarian area on histological slides, as a proxy for ovarian cysts,
were similar in both groups: 9.562.7% in the sirolimus group and
8.562.4% in the control group. The cycle lengths were similar
both groups: 764 days in the sirolimus group and 563 days in the
control group. The frequencies of abnormal cycles were higher
among rats receiving sirolimus: 50% in the sirolimus group and
16% in the control group. Sirolimus blocked the mTOR pathway
and amplified signaling in ovarian follicles through the pro-
proliferative phosphatidylinositol 3-kinase pathway (Figure 4).
Serum levels of follicle stimulating and luteinizing hormones
(FSH, LH) were similar between groups: FSH: 1.860.3 and
2.260.3 nanograms per milliliter in the sirolimus and control
groups respectively; LH: 3.460.7 and 3.160.4 nanograms per
milliliter in the sirolimus and control groups respectively.
Discussion
When given sirolimus at a relatively low dose for a median of 19
months, 52% of 21 patients with ADPKD reported menstrual
cycle abnormalities, compared to 17% of 18 patients in the control
group. Sirolimus also increased the risk of ovarian cysts, and one
patient was cystectomized after receiving sirolimus for five months.
With relatively few female patients, it is not possible to make
precise estimates but these increases in relative risk are potentially
large – with a fourfold increase or more possible.
Reports from other studies suggest a lower ovarian toxicity or
make no mention of it at all. In a multi-center placebo controlled
phase II trial, Kahan and colleagues did not report menstrual cycle
abnormalities in 47 female kidney allograft recipients receiving
sirolimus for 12 months [4]. In two multi-center placebo
controlled phase III trials, 180 and 149 female kidney allograft
recipients were given sirolimus for 12 and 6 months respectively
and there were no reports of menstrual cycle disturbance or
ovarian cysts among these patients [2,3]. This discrepancy is likely
explained by the systematic and prospective assessment for
menstrual cycle and ovarian cyst formation in our study which
was not done in these large multicenter studies.
Our findings of sirolimus associated ovarian toxicity are
supported by two reports of a higher frequency of oligoamenor-
rhea and ovarian cysts in pancreatic islet recipients treated with a
dual therapy of sirolimus and tacrolimus [6,7]. Cure and
colleagues reported a higher frequency of oligoamenorrhea after
transplantation and the occurrence of ovarian cysts in 8 of 13
patients, while serum follicle and luteinizing hormone levels
remained in the normal range [6]. Alfadhli and colleagues
reported on the occurrence of ovarian cysts in 31 of 44
premenopausal patients 8 months after transplantation and then
after sirolimus withdrawal, a cyst size reduction in 80% of these 31
patients [7].
Sirolimus-associated adverse events of this sort are usually not
assessed in randomized trials, even though normal menstrual cycle
recovery after successful organ transplantation is a major benefit
and a biological marker of general health, and menstrual cycle
abnormalities are a sign of lower fertility and are associated with
cardiovascular disease and bone loss.[32,33] In clinical practice,
sirolimus is often given simultaneously with other immunosup-
pressants making it difficult to reliably link observed ovarian
toxicity with a single immunosuppressive agent.
In our phase II trial, we enrolled patients with early stage
autosomal dominant polycystic kidney disease. The disease is
characterized by the cystic enlargement of both kidneys while
glomerular filtration rate remains preserved up to age 40 in most
patients [34,35]. There is no evidence that ADPKD affects the
menstrual cycle or fertility in woman with normal renal function
[11,36]. Cysts can also occur infrequently in organs other than the
kidneys;[37] however, the frequency of ovarian cysts, ovarian size
and follicle dimensions are no different in women with ADPKD
than in a normal population [9,10]. Our cyst measurements may
have included normal pre-ovulatory follicles as false positives.
Figure 2. Oligoamenorrhea (upper panel) and the size (lower panel; in millimeters) and the left-right location (R, L) of ovarian cysts
over time in the sirolimus (orange) and control (blue) groups.
doi:10.1371/journal.pone.0045868.g002
Table 3. The effect of treatment with sirolimus on the
prevalence and incidence of oligoamenorrhea and ovarian
cysts: odds and hazard ratios from logistic and Cox
proportional hazard regression.
Oligoamenorrhea Ovarian cysts
Estimate 95% CI Estimate 95% CI
Logistic regression – odds ratios
Profile likelihood 5.5 1.3 to 29 3.5 0.94 to 14
Exact 5.3 1.0 to 37 3.4 0.76 to 17
Cox proportional hazards regression – hazard ratios
Profile likelihood 4.3 1.1 to 29 4.0 1.1 to 26
Exact* 4.4 0.75 to 48 4.3 0.82 to 43
*Exact hazard ratios were estimated using a model with a logit link function and
no offset. Profile likelihood estimates for this alternative model were 4.5, (95%
confidence interval [CI] 1.1 to 31) and 4.6, (95% CI 0.99 to 34) for
oligoamenorrhea and ovarian cysts respectively.
doi:10.1371/journal.pone.0045868.t003
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However our analyses show that sirolimus increased the risk of
both ovarian cysts and menstrual cycle disturbances in patients
receiving sirolimus and these differences between randomized
groups suggest that the cysts detected in patients treated with
sirolimus were probably not normal.
The sirolimus target mTOR is a key regulatory kinase of cell
growth, proliferation and differentiation and is also expressed in
non-T-cells, which can lead to unexpected toxicities including the
ovaries. Animal studies indicate that the mTOR signaling pathway
regulates luteal hormone receptor action [38], the follicle-
stimulating hormone signaling pathway [39], granulosa [40] and
luteal [41] cell proliferation and control of primordial oocyte
dormancy [42]. Shivaswamy and colleagues reported an increased
frequency of abnormal cycles and hyperinsulinemia in Sprague-
Dawley rats receiving daily 2 milligrams sirolimus subcutaneously
for 4 weeks, but a similar frequency of abnormal ovarian follicles
in the their sirolimus and control groups [19]. We also observed an
increased frequency of abnormal cycles in Wistar rats receiving
sirolimus for 3 weeks, and a similar number and morphology of
ovarian follicles in our sirolimus and control groups.
Polycystic ovary syndrome (PCOS) manifests as menstrual cycle
disturbances, ovarian cysts, and insulin resistance [43]. Sirolimus
causes insulin resistance in rodents [19] and in humans [44,45]
and we observed cycle disturbance and ovarian cysts in our
ADPKD patients when treated with sirolimus, suggesting sirolimus
promotes a polycystic ovary like syndrome. In our animal study,
sirolimus activated Akt in ovaries. Polymorphisms of the Akt gene
were associated with an increased risk for the occurrence of PCOS
in epidemiological studies [46] and an increase in the insulin-
induced IRS/PI 3-kinase/Akt pathway in rat ovaries caused a
PCOS like phenotype [47], suggesting this pathway has a role in
the development of ovarian cysts.
Our results should be interpreted in the context of the trial
setting. Even though the achieved sirolimus dose was approxi-
mately 35% lower than the intended dose, mainly because of dose-
limiting gastrointestinal side effects, our findings show evidence of
sirolimus-associated ovarian toxicity. Close monitoring is therefore
Figure 3. Time course of adherence parameters (persistence and adherence) in patients assigned to the sirolimus group. The
persistence curve shows a Kaplan Meier estimation of the proportion of patients on treatment. The adherence curve indicates the day-to-day
proportion of patients who took sirolimus as prescribed. Data from 21 individual dosing histories were used for this analysis.
doi:10.1371/journal.pone.0045868.g003
Table 4. Sirolimus dosage, sirolimus steady-state blood level and parameters of treatment adherence in patients assigned to the
sirolimus group.
Months
Sirolimus dosage*
(milligram per day)
Sirolimus level*
(microgram per liter) Continuation{ (%) Adherence{ (%)
3 months 1.1 (0.5) 3.5 (1.0) 100 97.6
6 months 1.3 (0.4) 3.5 (1.1) 100 96.9
9 months 1.2 (0.6) 3.7 (1.1) 95.2 95.1
12 months 1.4 (0.4) 4.2 (1.9) 95.2 93.9
18 months 1.5 (0.5) 4.7 (1.6) 95.2 92.2
*Values are means (standard deviation).
{Continuation was defined as the proportion of patients who remained on the sirolimus treatment.
{Adherence was defined for each specific time interval as the average daily proportion of patients who took their sirolimus dose as prescribed among those still on the
sirolimus treatment.
doi:10.1371/journal.pone.0045868.t004
Toxicity of Sirolimus
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prudent for patients receiving sirolimus and this might help guide
clinical use of mTOR inhibitors.
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